$CYRX
Cryoport, Inc. Stock $cyrx

$cyrx Overview Financials Valuation SEC Filings Company Website

2015 Q2 Form 10-K Financial Statement

#000114420415032332 Filed on May 19, 2015

Income Statement

Concept	2015 Q2	2015 Q1	2015
Revenue	$1.431M	$1.198M	$3.935M
YoY Change	52.73%	43.47%	47.95%
Cost Of Revenue	$943.2K	$830.0K	$2.766M
YoY Change	57.92%	20.29%	24.44%
Gross Profit	$487.9K	$370.0K	$1.169M
YoY Change	43.93%	158.74%	167.52%
Gross Profit Margin	34.09%	30.88%	29.7%
Selling, General & Admin	$2.026M	$1.980M	$6.409M
YoY Change	41.92%	47.76%	25.52%
% of Gross Profit	415.31%	535.14%	548.31%
Research & Development	$77.72K	$90.00K	$352.6K
YoY Change	-1.92%	12.5%	-13.82%
% of Gross Profit	15.93%	24.32%	30.16%
Depreciation & Amortization	$45.67K	$40.00K	$197.9K
YoY Change	-17.17%	-20.0%	-36.47%
% of Gross Profit	9.36%	10.81%	16.93%
Operating Expenses	$2.104M	$2.060M	$6.762M
YoY Change	39.61%	45.07%	22.6%
Operating Profit	-$1.616M	-$1.693M	-$5.593M
YoY Change	38.37%	32.89%	10.13%
Interest Expense	$303.8K	-$240.0K	$1.428M
YoY Change	-73.09%	50.0%	82.04%
% of Operating Profit
Other Income/Expense, Net	-$975.00	$0.00	-$4.266K
YoY Change	-202.31%	-100.0%	-47.19%
Pretax Income	-$1.921M	-$1.940M	-$7.025M
YoY Change	-16.32%	34.72%	-64.09%
Income Tax	$3.320K	$1.600K	$1.600K
% Of Pretax Income
Net Earnings	-$1.924M	-$1.937M	-$7.027M
YoY Change	-16.23%	34.42%	-64.09%
Net Earnings / Revenue	-134.46%	-161.69%	-178.56%
Basic Earnings Per Share
Diluted Earnings Per Share	-$379.4K	-$386.5K	-$1.338M
COMMON SHARES
Basic Shares Outstanding	5.026M shares	60.06M shares
Diluted Shares Outstanding

Balance Sheet

Concept	2015 Q2	2015 Q1	2015
SHORT-TERM ASSETS
Cash & Short-Term Investments	$2.400M	$1.400M	$2.800M
YoY Change	1100.0%	250.0%	100.0%
Cash & Equivalents	$2.386M	$1.405M	$2.800M
Short-Term Investments
Other Short-Term Assets	$263.2K	$97.34K	$200.0K
YoY Change	223.29%	-50.47%	100.0%
Inventory	$104.8K	$69.68K	$100.0K
Prepaid Expenses
Receivables	$757.4K	$589.7K	$1.000M
Other Receivables	$0.00	$0.00	$0.00
Total Short-Term Assets	$3.511M	$2.162M	$4.100M
YoY Change	348.23%	94.48%	86.36%
LONG-TERM ASSETS
Property, Plant & Equipment	$381.4K	$307.9K	$1.300M
YoY Change	4.56%	-24.69%	333.33%
Goodwill
YoY Change
Intangibles
YoY Change
Long-Term Investments
YoY Change
Other Assets		$0.00	$400.0K
YoY Change
Total Long-Term Assets	$508.7K	$444.7K	$1.700M
YoY Change	-6.06%	-25.67%	325.0%
TOTAL ASSETS
Total Short-Term Assets	$3.511M	$2.162M	$4.100M
Total Long-Term Assets	$508.7K	$444.7K	$1.700M
Total Assets	$4.020M	$2.607M	$5.800M
YoY Change	203.42%	52.44%	123.08%
SHORT-TERM LIABILITIES
YoY Change
Accounts Payable	$600.0K	$800.0K	$1.300M
YoY Change	20.0%	33.33%	62.5%
Accrued Expenses	$400.0K	$700.0K	$500.0K
YoY Change	-20.0%	40.0%	-28.57%
Deferred Revenue
YoY Change
Short-Term Debt	$0.00	$1.500M	$0.00
YoY Change			-100.0%
Long-Term Debt Due	$1.000M	$0.00	$400.0K
YoY Change	-23.08%	-100.0%
Total Short-Term Liabilities	$1.973M	$2.996M	$2.200M
YoY Change	-17.8%	-25.36%	-26.67%
LONG-TERM LIABILITIES
Long-Term Debt	$0.00	$0.00	$600.0K
YoY Change
Other Long-Term Liabilities
YoY Change
Total Long-Term Liabilities	$0.00	$0.00	$600.0K
YoY Change
TOTAL LIABILITIES
Total Short-Term Liabilities	$1.973M	$2.996M	$2.200M
Total Long-Term Liabilities	$0.00	$0.00	$600.0K
Total Liabilities	$1.973M	$3.023M	$2.700M
YoY Change	-17.8%	-24.7%	-10.0%
SHAREHOLDERS EQUITY
Retained Earnings	-$104.2M	-$97.77M
YoY Change	17.15%	13.85%
Common Stock	$106.2M	$97.35M
YoY Change	20.89%	16.49%
Preferred Stock
YoY Change
Treasury Stock (at cost)
YoY Change
Treasury Stock Shares
Shareholders Equity	$2.047M	-$416.3K	$3.100M
YoY Change
Total Liabilities & Shareholders Equity	$4.020M	$2.607M	$5.800M
YoY Change	203.42%	52.44%	123.08%

Cashflow Statement

Concept	2015 Q2	2015 Q1	2015
OPERATING ACTIVITIES
Net Income	-$1.924M	-$1.937M	-$7.027M
YoY Change	-16.23%	34.42%	-64.09%
Depreciation, Depletion And Amortization	$45.67K	$40.00K	$197.9K
YoY Change	-17.17%	-20.0%	-36.47%
Cash From Operating Activities	-$1.870M	-$1.290M	-$6.310M
YoY Change	-303.93%	5.74%	52.78%
INVESTING ACTIVITIES
Capital Expenditures	$109.6K	$0.00	$70.13K
YoY Change			-49.51%
Acquisitions
YoY Change
Other Investing Activities
YoY Change
Cash From Investing Activities	-$110.0K	$0.00	-$1.120M
YoY Change			1500.0%
FINANCING ACTIVITIES
Cash Dividend Paid
YoY Change
Common Stock Issuance & Retirement, Net	$3.897M	$5.000M	$0.00
YoY Change
Debt Paid & Issued, Net
YoY Change
Cash From Financing Activities	2.960M	1.920M	8.810M
YoY Change	311.11%	40.15%	68.45%
NET CHANGE
Cash From Operating Activities	-1.870M	-1.290M	-6.310M
Cash From Investing Activities	-110.0K	0.000	-1.120M
Cash From Financing Activities	2.960M	1.920M	8.810M
Net Change In Cash	980.0K	630.0K	1.380M
YoY Change	6.87%	320.0%	33.98%
FREE CASH FLOW
Cash From Operating Activities	-$1.870M	-$1.290M	-$6.310M
Capital Expenditures	$109.6K	$0.00	$70.13K
Free Cash Flow	-$1.980M	-$1.290M	-$6.380M
YoY Change	-315.88%	5.74%	49.46%

Facts In Submission

Frame	Concept Type	Concept / XBRL Key	Value	Unit
CY2015	us-gaap	Use Of Estimates UseOfEstimates	<div style="MARGIN: 0pt 0px; FONT: 10pt Times New Roman, Times, Serif "> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;TEXT-INDENT: 0.5in; MARGIN: 0pt 0px; FONT: 10pt Times New Roman, Times, Serif" align="justify"></div> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;MARGIN: 0pt 0px; FONT: 10pt Times New Roman, Times, Serif" align="justify"><strong><i>Use of Estimates</i></strong></div> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;TEXT-INDENT: 24.5pt; MARGIN: 0pt 0px; FONT: 10pt Times New Roman, Times, Serif" align="justify"> </div> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;TEXT-INDENT: 24.5pt; MARGIN: 0pt 0px; FONT: 10pt Times New Roman, Times, Serif" align="justify">The preparation of financial statements in conformity with U.S. GAAP requires management to make estimates and assumptions that affect the reported amounts of assets and liabilities and disclosure of contingent assets and liabilities at the date of the financial statements and the reported amounts of revenues and expenses during the reporting periods. Actual results could differ from estimated amounts. The Company’s significant estimates include allowances for doubtful accounts, recoverability of long-lived assets, allowance for inventory obsolescence, deferred taxes and their accompanying valuations, and valuation of equity instruments and conversion features.</div> </div><table border="0" style="width:100%; table-layout:fixed;" cellspacing="0" cellpadding="0"><tr><td></td></tr></table>
CY2015	dei	Entity Voluntary Filers EntityVoluntaryFilers	No
CY2015	dei	Entity Current Reporting Status EntityCurrentReportingStatus	Yes
CY2015	dei	Entity Filer Category EntityFilerCategory	Smaller Reporting Company
CY2015	dei	Entity Well Known Seasoned Issuer EntityWellKnownSeasonedIssuer	No
CY2015	dei	Entity Central Index Key EntityCentralIndexKey	0001124524
CY2015	dei	Current Fiscal Year End Date CurrentFiscalYearEndDate	--03-31
CY2015	dei	Entity Registrant Name EntityRegistrantName	Cryoport, Inc.
CY2015Q1	us-gaap	Preferred Stock Shares Authorized PreferredStockSharesAuthorized	2500000	shares
CY2014Q1	us-gaap	Stock Issued During Period Shares Issued For Services StockIssuedDuringPeriodSharesIssuedForServices	150000	shares
CY2014Q1	us-gaap	Cash And Cash Equivalents At Carrying Value CashAndCashEquivalentsAtCarryingValue	369581	USD
CY2015Q1	us-gaap	Cash And Cash Equivalents At Carrying Value CashAndCashEquivalentsAtCarryingValue	1405186	USD
CY2014Q1	us-gaap	Accounts Receivable Net Current AccountsReceivableNetCurrent	515825	USD
CY2015Q1	us-gaap	Accounts Receivable Net Current AccountsReceivableNetCurrent	589699	USD
CY2014Q1	us-gaap	Inventory Net InventoryNet	29703	USD
CY2015Q1	us-gaap	Inventory Net InventoryNet	69680	USD
CY2014Q1	us-gaap	Other Assets Current OtherAssetsCurrent	196505	USD
CY2015Q1	us-gaap	Other Assets Current OtherAssetsCurrent	97337	USD
CY2014Q1	us-gaap	Assets Current AssetsCurrent	1111614	USD
CY2015Q1	us-gaap	Assets Current AssetsCurrent	2161902	USD
CY2014Q1	us-gaap	Property Plant And Equipment Net PropertyPlantAndEquipmentNet	408892	USD
CY2015Q1	us-gaap	Property Plant And Equipment Net PropertyPlantAndEquipmentNet	307926	USD
CY2014Q1	us-gaap	Finite Lived Intangible Assets Net FiniteLivedIntangibleAssetsNet	180086	USD
CY2015Q1	us-gaap	Finite Lived Intangible Assets Net FiniteLivedIntangibleAssetsNet	136821	USD
CY2014Q1	us-gaap	Deposits Assets DepositsAssets	9358	USD
CY2015Q1	us-gaap	Deposits Assets DepositsAssets	0	USD
CY2014Q1	us-gaap	Assets Assets	1709950	USD
CY2015Q1	us-gaap	Assets Assets	2606649	USD
CY2014Q1	us-gaap	Accounts Payable And Accrued Liabilities Current AccountsPayableAndAccruedLiabilitiesCurrent	579678	USD
CY2015Q1	us-gaap	Accounts Payable And Accrued Liabilities Current AccountsPayableAndAccruedLiabilitiesCurrent	758696	USD
CY2014Q1	us-gaap	Employee Related Liabilities Current EmployeeRelatedLiabilitiesCurrent	454288	USD
CY2015Q1	us-gaap	Employee Related Liabilities Current EmployeeRelatedLiabilitiesCurrent	725712	USD
CY2014Q1	us-gaap	Convertible Debt Current ConvertibleDebtCurrent	1622359	USD
CY2015Q1	us-gaap	Convertible Debt Current ConvertibleDebtCurrent	0	USD
CY2014Q1	us-gaap	Notes Payable Related Parties Classified Current NotesPayableRelatedPartiesClassifiedCurrent	1358120	USD
CY2015Q1	us-gaap	Notes Payable Related Parties Classified Current NotesPayableRelatedPartiesClassifiedCurrent	976581	USD
CY2014Q1	us-gaap	Liabilities Current LiabilitiesCurrent	4014445	USD
CY2015Q1	us-gaap	Liabilities Current LiabilitiesCurrent	2996496	USD
CY2014Q1	us-gaap	Commitments And Contingencies CommitmentsAndContingencies		USD
CY2015Q1	us-gaap	Commitments And Contingencies CommitmentsAndContingencies		USD
CY2014Q1	us-gaap	Preferred Stock Value PreferredStockValue		USD
CY2015Q1	us-gaap	Preferred Stock Value PreferredStockValue		USD
CY2014Q1	us-gaap	Common Stock Value CommonStockValue	4999	USD
CY2015Q1	us-gaap	Common Stock Value CommonStockValue	5026	USD
CY2014Q1	us-gaap	Additional Paid In Capital Common Stock AdditionalPaidInCapitalCommonStock	83567380	USD
CY2015Q1	us-gaap	Additional Paid In Capital Common Stock AdditionalPaidInCapitalCommonStock	97346137	USD
CY2014Q1	us-gaap	Retained Earnings Accumulated Deficit RetainedEarningsAccumulatedDeficit	-85876874	USD
CY2015Q1	us-gaap	Retained Earnings Accumulated Deficit RetainedEarningsAccumulatedDeficit	-97768079	USD
CY2014Q1	us-gaap	Stockholders Equity StockholdersEquity	-2304495	USD
CY2015Q1	us-gaap	Stockholders Equity StockholdersEquity	-416299	USD
CY2014Q1	us-gaap	Liabilities And Stockholders Equity LiabilitiesAndStockholdersEquity	1709950	USD
CY2015Q1	us-gaap	Liabilities And Stockholders Equity LiabilitiesAndStockholdersEquity	2606649	USD
CY2014	us-gaap	Net Income Loss NetIncomeLoss	-19565426	USD
CY2014	us-gaap	Other Preferred Stock Dividends And Adjustments OtherPreferredStockDividendsAndAdjustments	0	USD
CY2015	us-gaap	Interest Expense InterestExpense	1428015	USD
CY2015	us-gaap	Other Nonoperating Income Expense OtherNonoperatingIncomeExpense	-4266	USD
CY2015	us-gaap	Income Loss From Continuing Operations Before Income Taxes Minority Interest And Income Loss From Equity Method Investments IncomeLossFromContinuingOperationsBeforeIncomeTaxesMinorityInterestAndIncomeLossFromEquityMethodInvestments	-7025313	USD
CY2014Q1	us-gaap	Preferred Stock Shares Authorized PreferredStockSharesAuthorized	2500000	shares
CY2014Q1	us-gaap	Common Stock Par Or Stated Value Per Share CommonStockParOrStatedValuePerShare	0.001
CY2014Q1	us-gaap	Common Stock Shares Authorized CommonStockSharesAuthorized	20833333	shares
CY2014Q1	us-gaap	Common Stock Shares Issued CommonStockSharesIssued	4998330	shares
CY2015	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Fair Value Assumptions Expected Dividend Rate ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate	0	pure
CY2014Q1	us-gaap	Preferred Stock Par Or Stated Value Per Share PreferredStockParOrStatedValuePerShare	0.001
CY2014	us-gaap	Preferred Stock Dividends Income Statement Impact PreferredStockDividendsIncomeStatementImpact	0	USD
CY2014	us-gaap	Net Income Loss Available To Common Stockholders Basic NetIncomeLossAvailableToCommonStockholdersBasic	-19565426	USD
CY2015	us-gaap	Net Income Loss Available To Common Stockholders Basic NetIncomeLossAvailableToCommonStockholdersBasic	-12196533	USD
CY2015	us-gaap	Weighted Average Number Of Share Outstanding Basic And Diluted WeightedAverageNumberOfShareOutstandingBasicAndDiluted	5006219	shares
CY2014	us-gaap	Antidilutive Securities Excluded From Computation Of Earnings Per Share Amount AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount	556671	shares
CY2015	us-gaap	Antidilutive Securities Excluded From Computation Of Earnings Per Share Amount AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount	2397712	shares
CY2015Q1	us-gaap	Allowance For Doubtful Accounts Receivable AllowanceForDoubtfulAccountsReceivable	12200	USD
CY2015	cyrx	Maturity Period Of Highly Liquid Investments MaturityPeriodOfHighlyLiquidInvestments	P90D
CY2014Q1	us-gaap	Due To Related Parties Current And Noncurrent DueToRelatedPartiesCurrentAndNoncurrent	555500	USD
CY2015Q1	us-gaap	Due To Related Parties Current And Noncurrent DueToRelatedPartiesCurrentAndNoncurrent	1.3	USD
CY2015	us-gaap	Related Party Transaction Rate RelatedPartyTransactionRate	0.06	pure
CY2015	us-gaap	Debt Instrument Periodic Payment Principal DebtInstrumentPeriodicPaymentPrincipal	20000	USD
CY2014Q1	cyrx	Accrued Interest Payable AccruedInterestPayable	802600	USD
CY2015Q1	cyrx	Accrued Interest Payable AccruedInterestPayable	4600	USD
CY2015	cyrx	Minimum Amount Of Additional Compensation MinimumAmountOfAdditionalCompensation	2000000	USD
CY2015Q1	us-gaap	Common Stock Capital Shares Reserved For Future Issuance CommonStockCapitalSharesReservedForFutureIssuance	8810699	shares
CY2015Q1	us-gaap	Common Stock Shares Authorized CommonStockSharesAuthorized	20833333	shares
CY2015Q1	us-gaap	Common Stock Par Or Stated Value Per Share CommonStockParOrStatedValuePerShare	0.001
CY2015Q1	us-gaap	Preferred Stock Par Or Stated Value Per Share PreferredStockParOrStatedValuePerShare	0.001
CY2015	cyrx	Rate Of One Share For Each Dividend RateOfOneShareForEachDividend	4.80
CY2015Q1	us-gaap	Interest Payable Current And Noncurrent InterestPayableCurrentAndNoncurrent	24000	USD
CY2014	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Fair Value Assumptions Risk Free Interest Rate Minimum ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMinimum	0.0019	pure
CY2015	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Fair Value Assumptions Risk Free Interest Rate Minimum ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMinimum	0.0031	pure
CY2014	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Fair Value Assumptions Risk Free Interest Rate Maximum ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMaximum	0.0184	pure
CY2015	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Fair Value Assumptions Risk Free Interest Rate Maximum ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMaximum	0.0203	pure
CY2014	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Fair Value Assumptions Expected Volatility Rate Minimum ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMinimum	1.27	pure
CY2015	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Fair Value Assumptions Expected Volatility Rate Minimum ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMinimum	1.03	pure
CY2014	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Fair Value Assumptions Expected Volatility Rate Maximum ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMaximum	1.4	pure
CY2015	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Fair Value Assumptions Expected Volatility Rate Maximum ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMaximum	1.28	pure
CY2014	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Fair Value Assumptions Expected Dividend Rate ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate	0	pure
CY2015Q1	us-gaap	Common Stock Shares Issued CommonStockSharesIssued	5025577	shares
CY2014Q1	us-gaap	Common Stock Shares Outstanding CommonStockSharesOutstanding	4998330	shares
CY2015Q1	us-gaap	Common Stock Shares Outstanding CommonStockSharesOutstanding	5025577	shares
CY2014	us-gaap	Sales Revenue Net SalesRevenueNet	2659943	USD
CY2015	us-gaap	Sales Revenue Net SalesRevenueNet	3935320	USD
CY2014	us-gaap	Cost Of Revenue CostOfRevenue	2222988	USD
CY2015	us-gaap	Cost Of Revenue CostOfRevenue	2766391	USD
CY2014	us-gaap	Gross Profit GrossProfit	436955	USD
CY2015	us-gaap	Gross Profit GrossProfit	1168929	USD
CY2014	us-gaap	Selling General And Administrative Expense SellingGeneralAndAdministrativeExpense	5106219	USD
CY2015	us-gaap	Selling General And Administrative Expense SellingGeneralAndAdministrativeExpense	6409381	USD
CY2014	us-gaap	Research And Development Expense ResearchAndDevelopmentExpense	409111	USD
CY2015	us-gaap	Research And Development Expense ResearchAndDevelopmentExpense	352580	USD
CY2014	us-gaap	Operating Expenses OperatingExpenses	5515330	USD
CY2015	us-gaap	Operating Expenses OperatingExpenses	6761961	USD
CY2014	us-gaap	Operating Income Loss OperatingIncomeLoss	-5078375	USD
CY2015	us-gaap	Operating Income Loss OperatingIncomeLoss	-5593032	USD
CY2014	us-gaap	Induced Conversion Of Convertible Debt Expense InducedConversionOfConvertibleDebtExpense	13713767	USD
CY2015	us-gaap	Induced Conversion Of Convertible Debt Expense InducedConversionOfConvertibleDebtExpense	0	USD
CY2014	us-gaap	Interest Expense InterestExpense	784454	USD
CY2014	us-gaap	Other Nonoperating Income Expense OtherNonoperatingIncomeExpense	-8078	USD
CY2014	us-gaap	Unrealized Gain Loss On Derivatives UnrealizedGainLossOnDerivatives	20848	USD
CY2015	us-gaap	Unrealized Gain Loss On Derivatives UnrealizedGainLossOnDerivatives	0	USD
CY2014	us-gaap	Income Loss From Continuing Operations Before Income Taxes Minority Interest And Income Loss From Equity Method Investments IncomeLossFromContinuingOperationsBeforeIncomeTaxesMinorityInterestAndIncomeLossFromEquityMethodInvestments	-19563826	USD
CY2014	us-gaap	Income Tax Expense Benefit IncomeTaxExpenseBenefit	1600	USD
CY2015	us-gaap	Income Tax Expense Benefit IncomeTaxExpenseBenefit	1600	USD
CY2015	us-gaap	Net Income Loss NetIncomeLoss	-7026913	USD
CY2015	us-gaap	Other Preferred Stock Dividends And Adjustments OtherPreferredStockDividendsAndAdjustments	4864292	USD
CY2015	us-gaap	Preferred Stock Dividends Income Statement Impact PreferredStockDividendsIncomeStatementImpact	305328	USD
CY2014	us-gaap	Depreciation Depletion And Amortization DepreciationDepletionAndAmortization	311590	USD
CY2015	us-gaap	Depreciation Depletion And Amortization DepreciationDepletionAndAmortization	197938	USD
CY2014	us-gaap	Amortization Of Debt Discount Premium AmortizationOfDebtDiscountPremium	678915	USD
CY2015	us-gaap	Amortization Of Debt Discount Premium AmortizationOfDebtDiscountPremium	1368305	USD
CY2014	us-gaap	Share Based Compensation ShareBasedCompensation	678119	USD
CY2015	us-gaap	Share Based Compensation ShareBasedCompensation	881706	USD
CY2014	us-gaap	Disposal Group Not Discontinued Operation Gain Loss On Disposal DisposalGroupNotDiscontinuedOperationGainLossOnDisposal	-16066	USD
CY2015	us-gaap	Disposal Group Not Discontinued Operation Gain Loss On Disposal DisposalGroupNotDiscontinuedOperationGainLossOnDisposal	-16423	USD
CY2014	us-gaap	Provision For Doubtful Accounts ProvisionForDoubtfulAccounts	24876	USD
CY2015	us-gaap	Provision For Doubtful Accounts ProvisionForDoubtfulAccounts	2713	USD
CY2014	us-gaap	Increase Decrease In Accounts Receivable IncreaseDecreaseInAccountsReceivable	323604	USD
CY2015	us-gaap	Increase Decrease In Accounts Receivable IncreaseDecreaseInAccountsReceivable	76587	USD
CY2014	us-gaap	Increase Decrease In Inventories IncreaseDecreaseInInventories	-9509	USD
CY2015	us-gaap	Increase Decrease In Inventories IncreaseDecreaseInInventories	39977	USD
CY2014	us-gaap	Increase Decrease In Other Operating Assets IncreaseDecreaseInOtherOperatingAssets	26588	USD
CY2015	us-gaap	Increase Decrease In Other Operating Assets IncreaseDecreaseInOtherOperatingAssets	-10174	USD
CY2014	us-gaap	Increase Decrease In Accounts Payable And Accrued Liabilities IncreaseDecreaseInAccountsPayableAndAccruedLiabilities	-221929	USD
CY2015	us-gaap	Increase Decrease In Accounts Payable And Accrued Liabilities IncreaseDecreaseInAccountsPayableAndAccruedLiabilities	209138	USD
CY2014	us-gaap	Increase Decrease In Employee Related Liabilities IncreaseDecreaseInEmployeeRelatedLiabilities	236856	USD
CY2015	us-gaap	Increase Decrease In Employee Related Liabilities IncreaseDecreaseInEmployeeRelatedLiabilities	271424	USD
CY2014	us-gaap	Increase Decrease In Interest Payable Net IncreaseDecreaseInInterestPayableNet	108038	USD
CY2015	us-gaap	Increase Decrease In Interest Payable Net IncreaseDecreaseInInterestPayableNet	57954	USD
CY2014	us-gaap	Net Cash Provided By Used In Operating Activities Continuing Operations NetCashProvidedByUsedInOperatingActivitiesContinuingOperations	-4380659	USD
CY2015	us-gaap	Net Cash Provided By Used In Operating Activities Continuing Operations NetCashProvidedByUsedInOperatingActivitiesContinuingOperations	-4127702	USD
CY2014	us-gaap	Payments To Acquire Property Plant And Equipment PaymentsToAcquirePropertyPlantAndEquipment	138886	USD
CY2015	us-gaap	Payments To Acquire Property Plant And Equipment PaymentsToAcquirePropertyPlantAndEquipment	70130	USD
CY2014	us-gaap	Net Cash Provided By Used In Investing Activities Continuing Operations NetCashProvidedByUsedInInvestingActivitiesContinuingOperations	-138886	USD
CY2015	us-gaap	Net Cash Provided By Used In Investing Activities Continuing Operations NetCashProvidedByUsedInInvestingActivitiesContinuingOperations	-70130	USD
CY2014	us-gaap	Proceeds From Issuance Of Preferred Stock And Preference Stock ProceedsFromIssuanceOfPreferredStockAndPreferenceStock	0	USD
CY2015	us-gaap	Proceeds From Issuance Of Preferred Stock And Preference Stock ProceedsFromIssuanceOfPreferredStockAndPreferenceStock	4607571	USD
CY2014	us-gaap	Proceeds From Issuance Of Warrants ProceedsFromIssuanceOfWarrants	326890	USD
CY2015	us-gaap	Proceeds From Issuance Of Warrants ProceedsFromIssuanceOfWarrants	92609	USD
CY2014	us-gaap	Proceeds From Convertible Debt ProceedsFromConvertibleDebt	4558301	USD
CY2015	us-gaap	Proceeds From Convertible Debt ProceedsFromConvertibleDebt	0	USD
CY2014	us-gaap	Repayments Of Convertible Debt RepaymentsOfConvertibleDebt	0	USD
CY2015	us-gaap	Repayments Of Convertible Debt RepaymentsOfConvertibleDebt	50000	USD
CY2014	us-gaap	Payments Of Financing Costs PaymentsOfFinancingCosts	463169	USD
CY2015	us-gaap	Payments Of Financing Costs PaymentsOfFinancingCosts	30120	USD
CY2014	us-gaap	Repayments Of Related Party Debt RepaymentsOfRelatedPartyDebt	96000	USD
CY2015	us-gaap	Repayments Of Related Party Debt RepaymentsOfRelatedPartyDebt	128000	USD
CY2014	us-gaap	Net Cash Provided By Used In Financing Activities Continuing Operations NetCashProvidedByUsedInFinancingActivitiesContinuingOperations	4326022	USD
CY2015	us-gaap	Net Cash Provided By Used In Financing Activities Continuing Operations NetCashProvidedByUsedInFinancingActivitiesContinuingOperations	5233437	USD
CY2014	us-gaap	Net Cash Provided By Used In Continuing Operations NetCashProvidedByUsedInContinuingOperations	-193523	USD
CY2015	us-gaap	Net Cash Provided By Used In Continuing Operations NetCashProvidedByUsedInContinuingOperations	1035605	USD
CY2013Q1	us-gaap	Cash And Cash Equivalents At Carrying Value CashAndCashEquivalentsAtCarryingValue	563104	USD
CY2014	cyrx	Deferred Financing Costs In Connection With Convertible Debt Payable Included In Accounts Payable DeferredFinancingCostsInConnectionWithConvertibleDebtPayableIncludedInAccountsPayable	30120	USD
CY2015	cyrx	Deferred Financing Costs In Connection With Convertible Debt Payable Included In Accounts Payable DeferredFinancingCostsInConnectionWithConvertibleDebtPayableIncludedInAccountsPayable	0	USD
CY2014	cyrx	Debt Conversion Converted Instrument Amount Warrant Issued DebtConversionConvertedInstrumentAmountWarrantIssued	478229	USD
CY2015	cyrx	Debt Conversion Converted Instrument Amount Warrant Issued DebtConversionConvertedInstrumentAmountWarrantIssued	0	USD
CY2014	cyrx	Convertible Preferred Stock Beneficial Conversion Feature And Fair Value Of Warrants Issued ConvertiblePreferredStockBeneficialConversionFeatureAndFairValueOfWarrantsIssued	0	USD
CY2015	cyrx	Convertible Preferred Stock Beneficial Conversion Feature And Fair Value Of Warrants Issued ConvertiblePreferredStockBeneficialConversionFeatureAndFairValueOfWarrantsIssued	4864292	USD
CY2014	us-gaap	Debt Conversion Converted Instrument Amount1 DebtConversionConvertedInstrumentAmount1	4127201	USD
CY2015	us-gaap	Debt Conversion Converted Instrument Amount1 DebtConversionConvertedInstrumentAmount1	0	USD
CY2014	us-gaap	Debt Conversion Original Debt Amount1 DebtConversionOriginalDebtAmount1	0	USD
CY2015	us-gaap	Debt Conversion Original Debt Amount1 DebtConversionOriginalDebtAmount1	1766997	USD
CY2015	us-gaap	Nature Of Operations NatureOfOperations	<div style="MARGIN: 0pt 0px; FONT: 10pt Times New Roman, Times, Serif "> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;MARGIN: 0pt 0px; FONT: 10pt Times New Roman, Times, Serif" align="justify"><b>Note 1. Nature of the Business</b></div> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;TEXT-INDENT: 0.5in; MARGIN: 0pt 0px; FONT: 10pt Times New Roman, Times, Serif">  </div> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;TEXT-INDENT: 27pt; MARGIN: 0pt 0px; FONT: 10pt Times New Roman, Times, Serif" align="justify">Cryoport Inc. (the “Company”, “Cryoport”, “we” or “our”) is a Nevada corporation originally incorporated under the name G.T.5-Limited (“GT5”) on May 25, 1990. In connection with a Share Exchange Agreement, on March 15, 2005 we changed our name to Cryoport, Inc. and acquired all of the issued and outstanding shares of common stock of Cryoport Systems, Inc., a California corporation, in exchange for <font style="FONT-FAMILY: 'Times New Roman','serif'; FONT-SIZE: 10pt"> 200,901</font> shares of our common stock (which represented approximately <font style="FONT-FAMILY: 'Times New Roman','serif'; FONT-SIZE: 10pt"> 81</font>% of the total issued and outstanding shares of common stock following the close of the transaction). Cryoport Systems, Inc., which was originally formed in 1999 as a California limited liability company, and subsequently reorganized into a California corporation on December 11, 2000, remains an operating company under Cryoport, Inc. We became “publicly held” by the reverse merger with GT5 described above. Over time the Company transitioned from being a development company to a fully operational public company in early 2011, providing global cryogenic logistics solutions to the biotechnology and life sciences industries.</div> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;TEXT-INDENT: 27pt; MARGIN: 0pt 0px; FONT: 10pt Times New Roman, Times, Serif" align="justify"> </div> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;TEXT-INDENT: 24.5pt; MARGIN: 0pt 0px; FONT: 10pt Times New Roman, Times, Serif" align="justify">The Company became public by a reverse merger with a shell company in May 2005. Over time the Company has transitioned from being a development company to a fully operational public company, providing cold chain logistics solutions to the biotechnology and life sciences industries globally.</div> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;MARGIN: 0pt 0px; FONT: 10pt Times New Roman, Times, Serif" align="justify"> </div> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;TEXT-INDENT: 24.5pt; MARGIN: 0pt 0px; FONT: 10pt Times New Roman, Times, Serif" align="justify">Since fiscal year 2011, the Company has taken significant steps towards commercialization of the Cryoport Express<sup style="font-style:normal">®</sup> logistics solutions in validating, perfecting and expanding its features. The Company has now managed shipments of its Cryoport Express<sup style="font-style:normal">®</sup> Shippers through its Cryoportal<sup style="font-style:normal">TM</sup> into and out of more than 80 countries, handling a vast array of different biological products and specimens.</div> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;TEXT-INDENT: 27pt; MARGIN: 0pt 0px; FONT: 10pt Times New Roman, Times, Serif" align="justify"> </div> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;TEXT-INDENT: 24.5pt; MARGIN: 0pt 0px; FONT: 10pt Times New Roman, Times, Serif" align="justify">We provide cryogenic logistics solutions to the life sciences industry through a combination of purpose-built proprietary packaging, information technology and specialized cold chain logistics knowhow. We view our solutions as disruptive to the “older technologies” of dry ice and liquid nitrogen, in that our solutions are comprehensive and combine our competencies in configurations that are customized to our client’s requirements. We provide comprehensive, reliable, economic alternatives to all existing logistics solutions and services utilized for frozen shipping in the life sciences industry (e.g., personalized medicine, stem cells, cell lines, vaccines, diagnostic materials, semen, eggs, embryos, cord blood, bio-pharmaceuticals, infectious substances, and other commodities that require continuous exposure to cryogenic or frozen temperatures). We provide the ability to monitor, record and archive crucial information for each shipment that can be used for scientific and regulatory purposes.</div> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;TEXT-INDENT: 24.5pt; MARGIN: 0pt 0px; FONT: 10pt Times New Roman, Times, Serif" align="justify"> </div> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;TEXT-INDENT: 24.5pt; MARGIN: 0pt 0px; FONT: 10pt Times New Roman, Times, Serif" align="justify">Our Cryoport Express<sup style="font-style:normal">®</sup> Solutions include a sophisticated cloud-based logistics operating platform, which is branded as the Cryoportal. The Cryoportal supports the management of the entire shipment and logistics process through a single interface, including initial order input, document preparation, customs clearance, courier management, shipment tracking, issue resolution, and delivery. In addition, it provides unique and incisive information dashboards and validation documentation for every shipment. The Cryoportal records and retains a fully documented “chain-of-custody” and, at the client’s option, “chain-of-condition” for every shipment, helping ensure that quality, safety, efficacy, and stability of shipped commodities are maintained throughout the process. This recorded and archived information allows our clients to meet exacting requirements necessary for scientific work and for proof of regulatory compliance during the logistics phase.</div> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;TEXT-INDENT: 0.5in; MARGIN: 0pt 0px; FONT: 10pt Times New Roman, Times, Serif">   </div> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;TEXT-INDENT: 24.5pt; MARGIN: 0pt 0px; FONT: 10pt Times New Roman, Times, Serif" align="justify">The branded packaging for our Cryoport Express<sup style="font-style:normal">®</sup> Solutions includes our liquid nitrogen dry vapor shippers, the Cryoport Express<sup style="font-style:normal">®</sup> Shippers. The Cryoport Express<sup style="font-style:normal">®</sup> Shippers <sup style="font-style:normal"></sup>are cost-effective and reusable cryogenic transport containers (our standard shipper is a patented vacuum flask) utilizing an innovative application of “dry vapor” liquid nitrogen (“LN2”) technology. Cryoport Express<sup style="font-style:normal">®</sup> Shippers are International Air Transport Association (“IATA”) certified and validated to maintain stable temperatures of minus 150° C and below for a 10-day dynamic shipment period. The Company currently features three Cryoport Express<sup style="font-style:normal">®</sup> Shippers: the Standard Dry Shipper (holding up to 75 2.0 ml vials), the High Volume Dry Shipper (holding up to 500 2.0 ml vials) and the recently introduced Cryoport Express<sup style="font-style:normal">®</sup> CXVC1 Shipper (holding up to 1,500 2.0 ml vials). In addition, we assist clients with internal secondary packaging as well (e.g., vials, canes, straws, plates, etc.)</div> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;TEXT-INDENT: 24.5pt; MARGIN: 0pt 0px; FONT: 10pt Times New Roman, Times, Serif" align="justify"> </div> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;TEXT-INDENT: 24.5pt; MARGIN: 0pt 0px; FONT: 10pt Times New Roman, Times, Serif" align="justify">Our most used solution is the “turnkey” solution, which can be accessed directly through our cloud-based Cryoportal or by contacting Cryoport Client Care for order entry. Once an order is placed and cleared, we ship a fully charged Cryoport Express<sup style="font-style:normal">®</sup> Shipper to the client <font style="COLOR: #1a1a1a">who conveniently loads its frozen commodity into the inner chamber of the</font> Cryoport Express<sup style="font-style:normal">®</sup> Shipper<font style="COLOR: #1a1a1a">.  The customer then closes the shipper package and reseals the shipping box displaying the next recipient’s address (“Flap A”) for pre-arranged carrier pick up. </font> Cryoport arranges for the pick-up of the parcel by a shipping service provider, which is designated by the client or chosen by Cryoport, for delivery to the client’s intended recipient.  The recipient simply opens the shipper package and removes the frozen commodity that has been shipped.  The recipient then reseals the package, displaying the nearest Cryoport Operations Center address (“Flap B”), making it ready for pre-arranged carrier pick-up. The When the Cryoport Operations Center receives the Cryoport Express<sup style="font-style:normal">®</sup> Shipper, it is cleaned, put through quality assurance testing, and returned to inventory for reuse.</div> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt">  </div> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;TEXT-INDENT: 24.5pt; MARGIN: 0pt 0px; FONT: 10pt Times New Roman, Times, Serif" align="justify">In late 2012, we shifted our focus to become a comprehensive cryogenic logistics solutions provider. Recognizing that clients in the life sciences industry have varying requirements, we unbundled our technologies, establishing customer facing solutions and taking a consultative approach to the market. Today, in addition to our standard “Turn-key Solution,” described above, we also provide the following customer facing, value-added solutions to address our various clients’ needs:</div> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;TEXT-INDENT: 24.5pt; MARGIN: 0pt 0px 0pt 0.5in; FONT: 10pt Times New Roman, Times, Serif" align="justify"> </div> <table style="WIDTH: 100%; BORDER-COLLAPSE: collapse; FONT: 10pt Times New Roman, Times, Serif" cellspacing="0" cellpadding="0"> <tr style="VERTICAL-ALIGN: top"> <td style="WIDTH: 0%"> <div> </div> </td> <td style="WIDTH: 24px"> <div><font style="FONT-FAMILY:Symbol">·</font></div> </td> <td style="TEXT-ALIGN: justify"> <div><font style="FONT-SIZE: 10pt">“<b><i>Customer Staged Solution</i></b>,” designed for clients making 50 or more shipments per month. Under this solution, we supply an inventory of our Cryoport Express<sup style="font-style:normal">®</sup> Shippers to our customer, in an uncharged state, enabling our customer (after training/certification) to charge them with liquid nitrogen and use our Cryoportal to enter orders with shipping and delivery service providers for the transportation of the package. Once the order is released, our customer services professionals monitor the shipment and the return of the shipper to us for cleaning, quality assurance testing and reuse.</font></div> </td> </tr> </table> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;TEXT-INDENT: -0.25in; MARGIN: 0pt 0px 0pt 0.5in; FONT: 10pt Times New Roman, Times, Serif" align="justify"> </div> <table style="WIDTH: 100%; BORDER-COLLAPSE: collapse; FONT: 10pt Times New Roman, Times, Serif" cellspacing="0" cellpadding="0"> <tr style="VERTICAL-ALIGN: top"> <td style="WIDTH: 0%"> <div> </div> </td> <td style="WIDTH: 24px"> <div><font style="FONT-FAMILY:Symbol">·</font></div> </td> <td style="TEXT-ALIGN: justify"> <div><font style="FONT-SIZE: 10pt">“<b><i>Customer Managed Solution</i></b>,” a limited customer implemented solution whereby we supply our Cryoport Express<sup style="font-style:normal">®</sup> Shippers to clients in a fully charged state, but leaving it to the client to manage the shipping, including the selection of the shipping and delivery service provider and the return of the shipper to us. .</font></div> </td> </tr> </table> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;TEXT-INDENT: -0.25in; MARGIN: 0pt 0px 0pt 0.5in; FONT: 10pt Times New Roman, Times, Serif" align="justify"> </div> <table style="WIDTH: 100%; BORDER-COLLAPSE: collapse; FONT: 10pt Times New Roman, Times, Serif" cellspacing="0" cellpadding="0"> <tr style="VERTICAL-ALIGN: top"> <td style="WIDTH: 0%"> <div> </div> </td> <td style="WIDTH: 24px"> <div><font style="FONT-FAMILY:Symbol">·</font></div> </td> <td style="TEXT-ALIGN: justify"> <div><font style="FONT-SIZE: 10pt">“<b><i>powered by Cryoport</i></b><sup style="font-style:normal">SM</sup>,” available to providers of shipping and delivery services who seek to offer a “branded” cryogenic logistics solution as part of their service offerings, with “<i>powered by Cryoport<sup style="font-style:normal">SM</sup></i>” appearing prominently on the offering software interface and packaging. This solution can also be private labeled upon meeting certain requirements, such as minimum required shipping volumes.</font></div> </td> </tr> </table> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;TEXT-INDENT: -0.25in; MARGIN: 0pt 0px 0pt 0.5in; FONT: 10pt Times New Roman, Times, Serif" align="justify">   </div> <table style="WIDTH: 100%; BORDER-COLLAPSE: collapse; FONT: 10pt Times New Roman, Times, Serif" cellspacing="0" cellpadding="0"> <tr style="VERTICAL-ALIGN: top"> <td style="WIDTH: 0%"> <div> </div> </td> <td style="WIDTH: 24px"> <div><font style="FONT-FAMILY:Symbol">·</font></div> </td> <td style="TEXT-ALIGN: justify"> <div><font style="FONT-SIZE: 10pt">“<b><i>Integrated Solution,</i></b>” <i></i>which is our outsource solution. It is our most comprehensive solution and involves our management of the entire cryogenic logistics process for our client, including Cryoport employees at the client’s site to manage the client’s cryogenic logistics function in total.</font></div> </td> </tr> </table> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;TEXT-INDENT: -0.25in; MARGIN: 0pt 0px 0pt 0.5in; FONT: 10pt Times New Roman, Times, Serif" align="justify"> </div> <table style="WIDTH: 100%; BORDER-COLLAPSE: collapse; FONT: 10pt Times New Roman, Times, Serif" cellspacing="0" cellpadding="0"> <tr style="VERTICAL-ALIGN: top"> <td style="WIDTH: 0%"> <div> </div> </td> <td style="WIDTH: 24px"> <div><font style="FONT-FAMILY:Symbol">·</font></div> </td> <td style="TEXT-ALIGN: justify"> <div><font style="FONT-SIZE: 10pt">“<b><i>Regenerative Medicine Point-of-Care Repository Solution,</i></b>” designed for allogeneic therapies. In this model we supply our Cryoport Express<sup style="font-style:normal">®</sup> Shipper to ship and store cryogenically preserved life science products for up to 6 days (or longer periods with supplementary shippers) at a point-of-care site, with the Cryoport Express<sup style="font-style:normal">®</sup> Shipper serving as a temporary freezer/repository enabling the efficient and effective distribution of temperature sensitive allogeneic cell-based therapies without the expense, inconvenience, and potential costly failure of an on-sight, cryopreservation device. Our customer service professionals monitor each shipment throughout the predetermined process including the return of the shipper to us. When the Cryoport Operations Center receives the Cryoport Express<sup style="font-style:normal">®</sup> Shipper package it is cleaned, put through quality assurance testing, and returned to inventory for reuse.</font></div> </td> </tr> </table> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;TEXT-INDENT: -0.25in; MARGIN: 0pt 0px 0pt 0.5in; FONT: 10pt Times New Roman, Times, Serif" align="justify">  </div> <table style="WIDTH: 100%; BORDER-COLLAPSE: collapse; FONT: 10pt Times New Roman, Times, Serif" cellspacing="0" cellpadding="0"> <tr style="VERTICAL-ALIGN: top"> <td style="WIDTH: 0%"> <div> </div> </td> <td style="WIDTH: 24px"> <div><font style="FONT-FAMILY:Symbol">·</font></div> </td> <td style="TEXT-ALIGN: justify"> <div><font style="FONT-SIZE: 10pt">“<b><i>Personalized Medicine and Cell-based Immunotherapy Solution,</i></b>” designed for autologous therapies. In this model our Cryoport Express<sup style="font-style:normal">®</sup> Shipper serves as an enabling technology for the safe transportation of manufactured autologous cellular-based immunotherapy market by providing a comprehensive logistics solution for the verified chain of custody and condition transport from, (a) the collection of the patient’s cells in a hospital setting, to (b) a central processing facility where they are manufactured into a personalized medicine, to (c) the safe, cryogenically preserved return of these irreplaceable cells to a point-of-care treatment facility.  If required, the Cryoport Express<sup style="font-style:normal">®</sup> Shipper can then serve as a temporary freezer/repository to allow the efficient distribution of this personalized medicine to the patient when and where the medical provider needs it most without the expense, inconvenience, and potential costly failure of an on-sight, cryopreservation device. Our customer services professionals monitor each shipment throughout the predetermined process, including the return of the shipper to us. When the Cryoport Operations Center receives the Cryoport Express<sup style="font-style:normal">®</sup> Shipper package it is cleaned, put through quality assurance testing, and returned to inventory for reuse.</font></div> </td> </tr> </table> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;TEXT-INDENT: 0.5in; MARGIN: 0pt 0px 0pt 0.5in; FONT: 10pt Times New Roman, Times, Serif" align="justify"> </div> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;MARGIN: 0pt 0px; FONT: 10pt Times New Roman, Times, Serif" align="justify"><b>Strategic Logistics Alliances</b></div> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;TEXT-INDENT: 24.5pt; MARGIN: 0pt 0px; FONT: 10pt Times New Roman, Times, Serif" align="justify"> </div> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;TEXT-INDENT: 24.5pt; MARGIN: 0pt 0px; FONT: 10pt Times New Roman, Times, Serif" align="justify">We have sought to establish strategic alliances as a method of marketing our solutions providing minus 150° C shipping conditions to the life sciences industry. We have focused our efforts on leading companies in the logistics services industry as well as participants in the life sciences industry. In connection with our alliances with providers of shipping services, we refer to their offerings as “<i>powered by Cryoport</i><sup style="font-style:normal">SM</sup>” to reflect our solutions being integrated into our alliance partner’s services.</div> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;TEXT-INDENT: 24.5pt; MARGIN: 0pt 0px; FONT: 10pt Times New Roman, Times, Serif" align="justify"> </div> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;TEXT-INDENT: 24.5pt; MARGIN: 0pt 0px; FONT: 10pt Times New Roman, Times, Serif" align="justify">Cryoport now serves and supports the three largest integrators in the world, responsible for over <font style="FONT-FAMILY: 'Times New Roman','serif'; FONT-SIZE: 10pt"> 85</font>% of worldwide airfreight, with its advanced cryogenic logistics solutions for life sciences. We operate with each independently and confidentially in support of their respective market and sales strategies. We maintain our independent partnerships with strict confidentiality guidelines within the Company. These agreements represent a significant validation of our solutions and the way we conduct our business.</div> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt">  </div> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;TEXT-INDENT: 24.5pt; MARGIN: 0pt 0px; FONT: 10pt Times New Roman, Times, Serif" align="justify"><b>FedEx.</b> In January 2013, we entered into a master agreement with Federal Express Corporation (“FedEx”) (the “FedEx Agreement”) renewing these services and providing FedEx with a non-exclusive license and right to use a customized version of our Cryoportal<sup style="font-style:normal">TM</sup> for the management of shipments made by FedEx customers. The FedEx Agreement became effective on January 1, 2013 and, unless sooner terminated as provided in the FedEx Agreement, expires on December 31, 2015. FedEx has the right to terminate this agreement at any time for convenience upon 180 days’ notice.</div> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;TEXT-INDENT: 24.5pt; MARGIN: 0pt 0px; FONT: 10pt Times New Roman, Times, Serif" align="justify"> </div> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;TEXT-INDENT: 24.5pt; MARGIN: 0pt 0px; FONT: 10pt Times New Roman, Times, Serif" align="justify">Under our FedEx Agreement, we provide frozen shipping logistics services through the combination of our purpose-built proprietary technologies and turnkey management processes. FedEx markets and sells Cryoport’s services for frozen temperature-controlled cold chain transportation as its FedEx<sup style="font-style:normal">®</sup> Deep Frozen Shipping Solution on a non-exclusive basis and at its sole expense. During fiscal year 2013, the Company worked closely with FedEx to further align its sales efforts and accelerate penetration within FedEx’s life sciences customer base through improved processes, sales incentives, joint customer calls and more frequent communication at the sales and executive level. In addition, FedEx has developed a FedEx branded version of the Cryoportal<sup style="font-style:normal">TM</sup> software platform, which is “<i>powered by Cryoport<sup style="font-style:normal">SM</sup></i>” for use by FedEx and its customers giving them access to the full capabilities of our cloud-based logistics management software platform.</div> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;TEXT-INDENT: 24.5pt; MARGIN: 0pt 0px; FONT: 10pt Times New Roman, Times, Serif" align="justify"><b> </b></div> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;TEXT-INDENT: 24.5pt; MARGIN: 0pt 0px; FONT: 10pt Times New Roman, Times, Serif" align="justify"><b>DHL.</b> In June 2014, we entered into a master agreement with LifeConEx, a part of DHL Global Forwarding (“DHL”). This relationship with DHL is a further implementation of the Company’s expansion of distribution partnerships under the “<i>powered by Cryoport<sup style="font-style:normal">SM</sup></i>” model described above, allowing us to expand our sales and marketing reach through our partners and build awareness of the benefits of our validated cryogenic solution offerings. DHL can now enhance and supplement its cold chain logistics offerings to its life sciences and healthcare customers with Cryoport’s validated cryogenic solutions. DHL added 15 additional certified Life Sciences stations in the second quarter of 2014 bringing the Thermonet network to 60 stations in operation. Over the course of rolling out our new relationship, this expanded network will offer Cryoport’s cryogenic solutions under the DHL brands as “<i>powered by Cryoport<sup style="font-style:normal">SM</sup></i>”. In addition, DHL’s customers will be able to have direct access to our cloud-based order entry and tracking portal to order Cryoport Express<sup style="font-style:normal">®</sup> Solutions and receive preferred DHL shipping rates and discounts. Our proprietary logistics management operating platform, the Cryoportal<sup style="font-style:normal">TM</sup>, is integrated with DHL’s tracking and billing systems to provide DHL life sciences and healthcare customers with a seamless way of accessing critical information regarding shipments of biological material worldwide.</div> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;TEXT-INDENT: 24.5pt; MARGIN: 0pt 0px; FONT: 10pt Times New Roman, Times, Serif" align="justify"> </div> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;TEXT-INDENT: 24.5pt; MARGIN: 0pt 0px; FONT: 10pt Times New Roman, Times, Serif" align="justify"><b>UPS.</b> In October 2014, we added United Parcel Services, Inc. (“UPS”) as our third major distributor by entering into an agreement with UPS Oasis Supply Corporation, a part of UPS, whereby UPS will offer our validated and comprehensive cryogenic solutions to its life sciences and healthcare customers on a global basis. This relationship with UPS is a further implementation of the Company’s expansion of distributors under the “<i>powered by Cryoport<sup style="font-style:normal">SM</sup></i>” model described above, allowing us to further expand our sales and marketing reach through our partners and build awareness of the benefits of our validated cryogenic solution offerings through UPS.</div> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;TEXT-INDENT: 0.5in; MARGIN: 0pt 0px; FONT: 10pt Times New Roman, Times, Serif" align="justify"> </div> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;TEXT-INDENT: 24.5pt; MARGIN: 0pt 0px; FONT: 10pt Times New Roman, Times, Serif" align="justify">Over the course of rolling out our new relationship with UPS, UPS customers will have direct access to our cloud-based order entry and tracking portal to order Cryoport Express<sup style="font-style:normal">®</sup> Solutions and gain access to UPS’s broad array of domestic and international shipping and logistics solutions at competitive prices. Our proprietary logistics management operating platform, the Cryoportal<sup style="font-style:normal">TM</sup>, is integrated with UPS’s tracking and billing systems to provide UPS life sciences and healthcare customers with a seamless way of accessing critical information regarding shipments of biological material worldwide.</div> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;TEXT-INDENT: 24.5pt; MARGIN: 0pt 0px; FONT: 10pt Times New Roman, Times, Serif" align="justify"> </div> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;TEXT-INDENT: 24.5pt; MARGIN: 0pt 0px; FONT: 10pt Times New Roman, Times, Serif" align="justify">These agreements the three largest integrators in the world represent a significant validation of our solutions and the way we conduct our business.</div> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;TEXT-INDENT: 0.5in; MARGIN: 0pt 0px; FONT: 10pt Times New Roman, Times, Serif" align="justify"> </div> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;MARGIN: 0pt 0px; FONT: 10pt Times New Roman, Times, Serif" align="justify"><b>Life Sciences Agreements</b></div> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;TEXT-INDENT: 24.5pt; MARGIN: 0pt 0px; FONT: 10pt Times New Roman, Times, Serif" align="justify"><b> </b></div> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;TEXT-INDENT: 24.5pt; MARGIN: 0pt 0px; FONT: 10pt Times New Roman, Times, Serif" align="justify"><b>Zoetis.</b> In December 2012, we signed an agreement with Pfizer Inc. relating to Zoetis Inc. (formerly the animal health business unit of Pfizer Inc.) pursuant to which we were engaged to manage frozen shipments of a key poultry vaccine. Under this arrangement, Cryoport provides on-site logistics personnel and its logistics management operating platform, the Cryoportal<sup style="font-style:normal">TM</sup> to manage shipments from the Zoetis manufacturing site in the United States to domestic customers as well as various international distribution centers. As part of our logistics management services, Cryoport is constantly analyzing logistics data and processes to further introduce economies and reliability throughout the network, ensuring products arrive at their destinations in specified conditions, on-time and with the optimum utilization of resources. The Company manages Zoetis’ total fleet of dewar flask shippers used for this purpose, including liquid nitrogen shippers. In July 2013 the agreement was amended to expand Cryoport’s scope to manage all logistics of Zoetis’ key frozen poultry vaccine to all Zoetis’ international distribution centers as well as all domestic shipments. In October 2013, the agreement was further amended to further expand Cryoport’s role to include the logistics management for a second poultry vaccine.</div> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt">  </div> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;TEXT-INDENT: 24.5pt; MARGIN: 0pt 0px; FONT: 10pt Times New Roman, Times, Serif" align="justify"><b>Liventa Biosciences.</b> In February 2014, we entered into a services agreement with Liventa Bioscience, Inc. (“Liventa”), a privately-held, commercial stage biotechnology company focused on cell-based, advanced biologics in the orthopedic industry. Under this agreement, Liventa will use Cryoport’s Regenerative MedicinePoint-of-Care Repository Solution for the logistics of its cell-based therapies requiring cryogenic temperatures and also provide Cryoport Express<sup style="font-style:normal">®</sup> Solutions to other biologics suppliers within the orthopedic arena. The agreement combines Cryoport’s proprietary, purpose-built cold chain logistics solutions for cell-based and advanced biologic tissue forms with Liventa’s distribution capability to orthopedic care providers. The implementation of Cryoport’s Regenerative MedicinePoint-of-Care Repository Solution will eliminate the risks of degradation and also eliminate the need for expensive onsite cryogenic freezers for storage of cell-based orthopedic therapies. This will enable Liventa to confidently serve orthopedic practices, surgical centers, pain clinics, hospitals and, eventually, pharmacies and specialty care providers. The agreement has an initial three-year term and may be renewed for consecutive three-year terms, unless earlier terminated by either party. Liventa also agreed to certain performance criteria and the issuance of <font style="FONT-FAMILY: 'Times New Roman','serif'; FONT-SIZE: 10pt"> 150,000</font> shares of its common stock to Cryoport in exchange for the exclusive right to offer, market and promote Cryoport Express<sup style="font-style:normal">®</sup> Solutions for cellular-based therapies requiring cryogenic temperatures for use in the orthopedic arena in the United States.</div> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;TEXT-INDENT: 24.5pt; MARGIN: 0pt 0px; FONT: 10pt Times New Roman, Times, Serif" align="justify"> </div> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;TEXT-INDENT: 24.5pt; MARGIN: 0pt 0px; FONT: 10pt Times New Roman, Times, Serif" align="justify">In summary, we serve the life sciences industry with cryogenic logistics solutions that are advanced, comprehensive, reliable, validated, and efficient. Our clients include those companies and institutions that have logistics requirements for personalized medicine, immunotherapies, stem cells, cell lines, tissue, vaccines, in-vitro fertilization, cord blood, and other temperature sensitive commodities of life sciences.</div> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;TEXT-INDENT: 24.5pt; MARGIN: 0pt 0px; FONT: 10pt Times New Roman, Times, Serif" align="justify"> </div> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;TEXT-INDENT: 0px; MARGIN: 0pt 0px; FONT: 10pt Times New Roman, Times, Serif" align="justify"><b><i>Going Concern</i></b><font style="FONT-FAMILY:Times New Roman, Times, Serif"> </font></div> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;TEXT-INDENT: 24.5pt; MARGIN: 0pt 0px; FONT: 10pt Times New Roman, Times, Serif" align="justify"> </div> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;TEXT-INDENT: 24.5pt; MARGIN: 0pt 0px; FONT: 10pt Times New Roman, Times, Serif" align="justify">The consolidated financial statements have been prepared using the accrual method of accounting in accordance with accounting principles generally accepted in the United States of America (“U.S. GAAP”) and have been prepared on a going concern basis, which contemplates the realization of assets and the settlement of liabilities in the normal course of business. We have sustained operating losses since our inception and have used substantial amounts of working capital in our operations. At March 31, 2015, we had an accumulated deficit of $<font style="FONT-FAMILY: 'Times New Roman','serif'; FONT-SIZE: 10pt">97.8</font> million. During the year ended March 31, 2015, we used cash in operations of $<font style="FONT-FAMILY: 'Times New Roman','serif'; FONT-SIZE: 10pt">4.1</font> million and had a net loss of $<font style="FONT-FAMILY: 'Times New Roman','serif'; FONT-SIZE: 10pt">7.0</font> million.</div> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;TEXT-INDENT: 24.5pt; MARGIN: 0pt 0px; FONT: 10pt Times New Roman, Times, Serif" align="justify"> </div> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;TEXT-INDENT: 27pt; MARGIN: 0pt 0px; FONT: 10pt Times New Roman, Times, Serif" align="justify"><font style="FONT-SIZE: 10pt">We expect to continue to incur substantial additional operating losses from costs related to the commercialization of our Cryoport Express<sup style="font-style:normal">®</sup></font> <font style="FONT-SIZE: 10pt">Solutions and do not expect that revenues from operations will be sufficient to satisfy our funding requirements in the near term. We believe that our cash resources at March 31, 2015, additional funds raised subsequent to March 31, 2015 through the Class B convertible preferred stock (see Note 15), together with the revenues generated from our services will be sufficient to sustain our planned operations into the third quarter of fiscal year 2016; however, we must obtain additional capital to fund operations thereafter and for the achievement of sustained profitable operations. These factors raise substantial doubt about our ability to continue as a going concern. We are currently working on funding alternatives in order to secure sufficient operating capital to allow us to continue to operate as a going concern.</font></div> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;TEXT-INDENT: 27pt; MARGIN: 0pt 0px; FONT: 10pt Times New Roman, Times, Serif" align="justify"> </div> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;TEXT-INDENT: 27pt; MARGIN: 0pt 0px; FONT: 10pt Times New Roman, Times, Serif" align="justify"><font style="FONT-SIZE: 10pt">Future capital requirements will depend upon many factors, including the success of our commercialization efforts and the level of customer adoption of our Cryoport Express<sup style="font-style:normal">®</sup></font> <font style="FONT-SIZE: 10pt">Solutions as well as our ability to establish additional collaborative arrangements. We cannot make any assurances that the sales ramp will lead to achievement of sustained profitable operations or that any additional financing will be completed on a timely basis and on acceptable terms or at all. Management’s inability to successfully achieve significant revenue increases or implement cost reduction strategies or to complete any other financing will adversely impact our ability to continue as a going concern. To address this issue, the Company is seeking additional capitalization to properly fund our efforts to become a self-sustaining financially viable entity.</font></div> </div><table border="0" style="width:100%; table-layout:fixed;" cellspacing="0" cellpadding="0"><tr><td></td></tr></table>
CY2014	cyrx	Debt Conversion Converted Instrument Amount Warrant Issued1 DebtConversionConvertedInstrumentAmountWarrantIssued1	0	USD
CY2015	cyrx	Debt Conversion Converted Instrument Amount Warrant Issued1 DebtConversionConvertedInstrumentAmountWarrantIssued1	458937	USD
CY2014	us-gaap	Proceeds From Notes Payable ProceedsFromNotesPayable	0	USD
CY2015	us-gaap	Proceeds From Notes Payable ProceedsFromNotesPayable	915000	USD
CY2014Q1	us-gaap	Notes Payable Current NotesPayableCurrent	0	USD
CY2015Q1	us-gaap	Notes Payable Current NotesPayableCurrent	535507	USD
CY2014Q4	us-gaap	Proceeds From Notes Payable ProceedsFromNotesPayable	915000	USD
CY2015	cyrx	Percentage Of Air Freight Supply PercentageOfAirFreightSupply	0.85	pure
CY2015	us-gaap	Preferred Stock Dividend Rate Per Dollar Amount PreferredStockDividendRatePerDollarAmount	0.96
CY2015Q2	dei	Entity Common Stock Shares Outstanding EntityCommonStockSharesOutstanding	5025577	shares
CY2015	dei	Trading Symbol TradingSymbol	CYRX
CY2005Q2	us-gaap	Stock Issued During Period Shares Acquisitions StockIssuedDuringPeriodSharesAcquisitions	200901	shares
CY2015	us-gaap	Concentration Risk Credit Risk ConcentrationRiskCreditRisk	<div style="MARGIN: 0pt 0px; FONT: 10pt Times New Roman, Times, Serif "> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;TEXT-INDENT: 0.5in; MARGIN: 0px; FONT: 10pt Times New Roman, Times, Serif" align="justify"></div> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;MARGIN: 0px; FONT: 10pt Times New Roman, Times, Serif" align="justify"><strong><i>Concentrations of Credit Risk</i></strong></div> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;TEXT-INDENT: 24.5pt; MARGIN: 0px; FONT: 10pt Times New Roman, Times, Serif" align="justify"> </div> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;TEXT-INDENT: 24.5pt; MARGIN: 0px; FONT: 10pt Times New Roman, Times, Serif" align="justify">The Company maintains its cash accounts in financial institutions. Accounts at these institutions are insured by the Federal Deposit Insurance Corporation (“FDIC”) with basic deposit insurance coverage limits up to $<font style="FONT-FAMILY: 'Times New Roman','serif'; FONT-SIZE: 10pt">250,000</font> per owner. At March 31, 2015 and 2014, the Company had cash balances of approximately $<font style="FONT-FAMILY: 'Times New Roman','serif'; FONT-SIZE: 10pt">1.3</font> million and $<font style="FONT-FAMILY: 'Times New Roman','serif'; FONT-SIZE: 10pt">159,000</font>, respectively, which exceeded the FDIC insurance limit. The Company performs ongoing evaluations of these institutions to limit its concentration risk exposure.</div> </div><table border="0" style="width:100%; table-layout:fixed;" cellspacing="0" cellpadding="0"><tr><td></td></tr></table>
CY2015Q1	us-gaap	Cash Fdic Insured Amount CashFDICInsuredAmount	250000	USD
CY2014Q1	us-gaap	Sales Revenue Net SalesRevenueNet	835000	USD
CY2015Q1	us-gaap	Sales Revenue Net SalesRevenueNet	1198000	USD
CY2013Q2	us-gaap	Sales Revenue Net SalesRevenueNet	488000	USD
CY2014Q2	us-gaap	Sales Revenue Net SalesRevenueNet	937000	USD
CY2013Q3	us-gaap	Sales Revenue Net SalesRevenueNet	580000	USD
CY2014Q3	us-gaap	Sales Revenue Net SalesRevenueNet	825000	USD
CY2013Q4	us-gaap	Sales Revenue Net SalesRevenueNet	757000	USD
CY2014Q4	us-gaap	Sales Revenue Net SalesRevenueNet	975000	USD
CY2014Q1	us-gaap	Gross Profit GrossProfit	143000	USD
CY2015Q1	us-gaap	Gross Profit GrossProfit	370000	USD
CY2013Q2	us-gaap	Gross Profit GrossProfit	55000	USD
CY2015Q1	us-gaap	Deferred Tax Assets Operating Loss Carryforwards DeferredTaxAssetsOperatingLossCarryforwards	16830000	USD
CY2014Q1	us-gaap	Deferred Tax Assets Tax Credit Carryforwards Research DeferredTaxAssetsTaxCreditCarryforwardsResearch	60000	USD
CY2015Q1	us-gaap	Deferred Tax Assets Tax Credit Carryforwards Research DeferredTaxAssetsTaxCreditCarryforwardsResearch	56000	USD
CY2014Q1	us-gaap	Deferred Tax Assets Tax Deferred Expense Compensation And Benefits Share Based Compensation Cost DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsShareBasedCompensationCost	1651000	USD
CY2015Q1	us-gaap	Deferred Tax Assets Tax Deferred Expense Compensation And Benefits Share Based Compensation Cost DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsShareBasedCompensationCost	1554000	USD
CY2014Q1	us-gaap	Deferred Tax Assets Tax Deferred Expense Reserves And Accruals DeferredTaxAssetsTaxDeferredExpenseReservesAndAccruals	135000	USD
CY2015Q1	us-gaap	Deferred Tax Assets Tax Deferred Expense Reserves And Accruals DeferredTaxAssetsTaxDeferredExpenseReservesAndAccruals	20000	USD
CY2014Q1	us-gaap	Deferred Tax Assets Valuation Allowance DeferredTaxAssetsValuationAllowance	17225000	USD
CY2014Q2	us-gaap	Gross Profit GrossProfit	339000	USD
CY2013Q3	us-gaap	Gross Profit GrossProfit	72000	USD
CY2014Q3	us-gaap	Gross Profit GrossProfit	225000	USD
CY2013Q4	us-gaap	Gross Profit GrossProfit	167000	USD
CY2014Q4	us-gaap	Gross Profit GrossProfit	235000	USD
CY2014Q1	us-gaap	Operating Income Loss OperatingIncomeLoss	-1274000	USD
CY2015Q1	us-gaap	Operating Income Loss OperatingIncomeLoss	-1693000	USD
CY2013Q2	us-gaap	Operating Income Loss OperatingIncomeLoss	-1260000	USD
CY2014Q2	us-gaap	Operating Income Loss OperatingIncomeLoss	-1168000	USD
CY2013Q3	us-gaap	Operating Income Loss OperatingIncomeLoss	-1287000	USD
CY2014Q3	us-gaap	Operating Income Loss OperatingIncomeLoss	-1375000	USD
CY2013Q4	us-gaap	Operating Income Loss OperatingIncomeLoss	-1257000	USD
CY2014Q4	us-gaap	Operating Income Loss OperatingIncomeLoss	-1357000	USD
CY2014Q1	us-gaap	Net Income Loss NetIncomeLoss	-1441000	USD
CY2015Q1	us-gaap	Net Income Loss NetIncomeLoss	-1937000	USD
CY2013Q2	us-gaap	Net Income Loss NetIncomeLoss	-1324000	USD
CY2014Q2	us-gaap	Net Income Loss NetIncomeLoss	-2297000	USD
CY2013Q3	us-gaap	Net Income Loss NetIncomeLoss	-14960000	USD
CY2014Q3	us-gaap	Net Income Loss NetIncomeLoss	-1385000	USD
CY2013Q4	us-gaap	Net Income Loss NetIncomeLoss	-1840000	USD
CY2014Q4	us-gaap	Net Income Loss NetIncomeLoss	-1408000	USD
CY2014Q1	us-gaap	Earnings Per Share Basic And Diluted EarningsPerShareBasicAndDiluted	-0.29
CY2015Q1	us-gaap	Earnings Per Share Basic And Diluted EarningsPerShareBasicAndDiluted	-0.79
CY2013Q2	us-gaap	Earnings Per Share Basic And Diluted EarningsPerShareBasicAndDiluted	-0.42
CY2014Q2	us-gaap	Earnings Per Share Basic And Diluted EarningsPerShareBasicAndDiluted	-0.61
CY2013Q3	us-gaap	Earnings Per Share Basic And Diluted EarningsPerShareBasicAndDiluted	-4.59
CY2014Q3	us-gaap	Earnings Per Share Basic And Diluted EarningsPerShareBasicAndDiluted	-0.64
CY2013Q4	us-gaap	Earnings Per Share Basic And Diluted EarningsPerShareBasicAndDiluted	-0.37
CY2014Q4	us-gaap	Earnings Per Share Basic And Diluted EarningsPerShareBasicAndDiluted	-0.40
CY2014Q1	us-gaap	Deferred Tax Assets Operating Loss Carryforwards DeferredTaxAssetsOperatingLossCarryforwards	15379000	USD
CY2015Q1	us-gaap	Income Tax Reconciliation Change In Deferred Tax Assets Valuation Allowance IncomeTaxReconciliationChangeInDeferredTaxAssetsValuationAllowance	1235000	USD
CY2015Q1	cyrx	Income Tax Reconciliation Warrant Adjustment IncomeTaxReconciliationWarrantAdjustment	0	USD
CY2015Q1	us-gaap	Deferred Tax Assets Valuation Allowance DeferredTaxAssetsValuationAllowance	18460000	USD
CY2014Q1	us-gaap	Deferred Tax Assets Net DeferredTaxAssetsNet	0	USD
CY2015Q1	us-gaap	Deferred Tax Assets Net DeferredTaxAssetsNet	0	USD
CY2014Q1	cyrx	Income Tax Reconciliation Induced Conversion Costs IncomeTaxReconciliationInducedConversionCosts	4663000	USD
CY2015Q1	cyrx	Income Tax Reconciliation Induced Conversion Costs IncomeTaxReconciliationInducedConversionCosts	0	USD
CY2014Q1	us-gaap	Income Tax Reconciliation Nondeductible Expense Other IncomeTaxReconciliationNondeductibleExpenseOther	0	USD
CY2015Q1	us-gaap	Income Tax Reconciliation Nondeductible Expense Other IncomeTaxReconciliationNondeductibleExpenseOther	462000	USD
CY2014Q1	us-gaap	Income Tax Reconciliation Other Reconciling Items IncomeTaxReconciliationOtherReconcilingItems	4600	USD
CY2015Q1	us-gaap	Income Tax Reconciliation Other Reconciling Items IncomeTaxReconciliationOtherReconcilingItems	873600	USD
CY2014Q1	us-gaap	Income Tax Reconciliation Change In Deferred Tax Assets Valuation Allowance IncomeTaxReconciliationChangeInDeferredTaxAssetsValuationAllowance	2318000	USD
CY2014Q1	us-gaap	Inventory Raw Materials InventoryRawMaterials	18283	USD
CY2015Q1	us-gaap	Inventory Raw Materials InventoryRawMaterials	41725	USD
CY2014Q1	us-gaap	Inventory Finished Goods InventoryFinishedGoods	11420	USD
CY2015Q1	us-gaap	Inventory Finished Goods InventoryFinishedGoods	27955	USD
CY2014Q1	us-gaap	Income Tax Reconciliation Income Tax Expense Benefit At Federal Statutory Income Tax Rate IncomeTaxReconciliationIncomeTaxExpenseBenefitAtFederalStatutoryIncomeTaxRate	-6650000	USD
CY2015Q1	us-gaap	Income Tax Reconciliation Income Tax Expense Benefit At Federal Statutory Income Tax Rate IncomeTaxReconciliationIncomeTaxExpenseBenefitAtFederalStatutoryIncomeTaxRate	-2382000	USD
CY2014Q1	us-gaap	Income Tax Reconciliation State And Local Income Taxes IncomeTaxReconciliationStateAndLocalIncomeTaxes	-327000	USD
CY2015Q1	us-gaap	Income Tax Reconciliation State And Local Income Taxes IncomeTaxReconciliationStateAndLocalIncomeTaxes	-187000	USD
CY2014Q1	cyrx	Income Tax Reconciliation Warrant Adjustment IncomeTaxReconciliationWarrantAdjustment	-7000	USD
CY2014Q1	us-gaap	Income Tax Expense Benefit IncomeTaxExpenseBenefit	1600	USD
CY2015Q1	us-gaap	Income Tax Expense Benefit IncomeTaxExpenseBenefit	1600	USD
CY2014Q1	us-gaap	Liabilities Liabilities	4014445	USD
CY2015Q1	us-gaap	Liabilities Liabilities	3022948	USD
CY2014Q1	us-gaap	Notes Payable Related Parties Noncurrent NotesPayableRelatedPartiesNoncurrent	0	USD
CY2015Q1	us-gaap	Notes Payable Related Parties Noncurrent NotesPayableRelatedPartiesNoncurrent	26452	USD
CY2014	us-gaap	Interest Paid InterestPaid	0	USD
CY2015	us-gaap	Interest Paid InterestPaid	753	USD
CY2014	us-gaap	Income Taxes Paid IncomeTaxesPaid	1600	USD
CY2015	us-gaap	Income Taxes Paid IncomeTaxesPaid	1600	USD
CY2015	us-gaap	Class Of Warrant Or Righst Date From Which Warrants Or Rights Exercisable ClassOfWarrantOrRighstDateFromWhichWarrantsOrRightsExercisable	2015-03-02
CY2015	cyrx	Class Of Warrant Or Rights Expiration Date ClassOfWarrantOrRightsExpirationDate	2020-03-01
CY2015	us-gaap	Proceeds From Issuance Of Common Stock ProceedsFromIssuanceOfCommonStock	5000000	USD
CY2014Q1	cyrx	Cryogenic Shippers CryogenicShippers	1037286	USD
CY2015Q1	cyrx	Cryogenic Shippers CryogenicShippers	1034554	USD
CY2014Q1	us-gaap	Furniture And Fixtures Gross FurnitureAndFixturesGross	30746	USD
CY2015Q1	us-gaap	Furniture And Fixtures Gross FurnitureAndFixturesGross	30746	USD
CY2014Q1	us-gaap	Machinery And Equipment Gross MachineryAndEquipmentGross	386731	USD
CY2015Q1	us-gaap	Machinery And Equipment Gross MachineryAndEquipmentGross	350520	USD
CY2014Q1	us-gaap	Leasehold Improvements Gross LeaseholdImprovementsGross	30913	USD
CY2015Q1	us-gaap	Leasehold Improvements Gross LeaseholdImprovementsGross	23652	USD
CY2014Q1	us-gaap	Property Plant And Equipment Gross PropertyPlantAndEquipmentGross	1485676	USD
CY2015Q1	us-gaap	Property Plant And Equipment Gross PropertyPlantAndEquipmentGross	1439472	USD
CY2014Q1	us-gaap	Accumulated Depreciation Depletion And Amortization Property Plant And Equipment AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment	1076784	USD
CY2015Q1	us-gaap	Accumulated Depreciation Depletion And Amortization Property Plant And Equipment AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment	1131546	USD
CY2014	us-gaap	Depreciation Depreciation	219400	USD
CY2015	us-gaap	Depreciation Depreciation	154700	USD
CY2013Q1	us-gaap	Stockholders Equity StockholdersEquity	-2063275	USD
CY2014	us-gaap	Adjustments To Additional Paid In Capital Sharebased Compensation Requisite Service Period Recognition Value AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue	678119	USD
CY2015	us-gaap	Adjustments To Additional Paid In Capital Sharebased Compensation Requisite Service Period Recognition Value AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue	864306	USD
CY2014	us-gaap	Stock Issued During Period Value Stock Options Exercised StockIssuedDuringPeriodValueStockOptionsExercised	326890	USD
CY2015	us-gaap	Stock Issued During Period Value Stock Options Exercised StockIssuedDuringPeriodValueStockOptionsExercised	92609	USD
CY2014	cyrx	Adjustments To Additional Paid In Capital Induced Conversion Costs AdjustmentsToAdditionalPaidInCapitalInducedConversionCosts	13713767	USD
CY2015Q1	us-gaap	Finite Lived Intangible Assets Amortization Expense Next Twelve Months FiniteLivedIntangibleAssetsAmortizationExpenseNextTwelveMonths	49800	USD
CY2015Q1	us-gaap	Finite Lived Intangible Assets Amortization Expense Year Two FiniteLivedIntangibleAssetsAmortizationExpenseYearTwo	28200	USD
CY2015Q1	us-gaap	Finite Lived Intangible Assets Amortization Expense Year Three FiniteLivedIntangibleAssetsAmortizationExpenseYearThree	19600	USD
CY2015Q1	us-gaap	Finite Lived Intangible Assets Amortization Expense Year Four FiniteLivedIntangibleAssetsAmortizationExpenseYearFour	19600	USD
CY2015Q1	us-gaap	Finite Lived Intangible Assets Amortization Expense Year Five FiniteLivedIntangibleAssetsAmortizationExpenseYearFive	19600	USD
CY2014Q1	us-gaap	Finite Lived Intangible Assets Gross FiniteLivedIntangibleAssetsGross	701341	USD
CY2015Q1	us-gaap	Finite Lived Intangible Assets Gross FiniteLivedIntangibleAssetsGross	701341	USD
CY2014Q1	us-gaap	Finite Lived Intangible Assets Accumulated Amortization FiniteLivedIntangibleAssetsAccumulatedAmortization	521255	USD
CY2015Q1	us-gaap	Finite Lived Intangible Assets Accumulated Amortization FiniteLivedIntangibleAssetsAccumulatedAmortization	564520	USD
CY2014	us-gaap	Amortization Of Intangible Assets AmortizationOfIntangibleAssets	92200	USD
CY2015	us-gaap	Amortization Of Intangible Assets AmortizationOfIntangibleAssets	43200	USD
CY2015	us-gaap	Repayments Of Notes Payable RepaymentsOfNotesPayable	173623	USD
CY2014	us-gaap	Repayments Of Notes Payable RepaymentsOfNotesPayable	0	USD
CY2015	cyrx	Debt Conversion Converted Instrument Related Party Amount Warrant Issued DebtConversionConvertedInstrumentRelatedPartyAmountWarrantIssued	280370	USD
CY2015Q1	us-gaap	Operating Leases Future Minimum Payments Due OperatingLeasesFutureMinimumPaymentsDue	38200	USD
CY2015Q1	us-gaap	Operating Leases Future Minimum Payments Due Current OperatingLeasesFutureMinimumPaymentsDueCurrent	27200	USD
CY2015Q1	us-gaap	Operating Leases Future Minimum Payments Due In Two Years OperatingLeasesFutureMinimumPaymentsDueInTwoYears	5500	USD
CY2014Q1	us-gaap	Accrued Salaries Current AccruedSalariesCurrent	80328	USD
CY2015Q1	us-gaap	Accrued Salaries Current AccruedSalariesCurrent	161241	USD
CY2014	us-gaap	Operating Leases Rent Expense Net OperatingLeasesRentExpenseNet	178000	USD
CY2015	us-gaap	Operating Leases Rent Expense Net OperatingLeasesRentExpenseNet	168900	USD
CY2014Q1	us-gaap	Accrued Vacation Current AccruedVacationCurrent	155166	USD
CY2015Q1	us-gaap	Accrued Vacation Current AccruedVacationCurrent	159992	USD
CY2014Q1	cyrx	Accrued Board Of Director Fees Current AccruedBoardOfDirectorFeesCurrent	214553	USD
CY2015Q1	cyrx	Accrued Board Of Director Fees Current AccruedBoardOfDirectorFeesCurrent	401532	USD
CY2014	cyrx	Consulting Service Fee ConsultingServiceFee	395300	USD
CY2015	cyrx	Consulting Service Fee ConsultingServiceFee	339300	USD
CY2014Q1	us-gaap	Other Employee Related Liabilities Current OtherEmployeeRelatedLiabilitiesCurrent	4241	USD
CY2015Q1	us-gaap	Other Employee Related Liabilities Current OtherEmployeeRelatedLiabilitiesCurrent	2947	USD
CY2014	us-gaap	Interest Expense Related Party InterestExpenseRelatedParty	36500	USD
CY2015	us-gaap	Interest Expense Related Party InterestExpenseRelatedParty	33500	USD
CY2015Q1	us-gaap	Class Of Warrant Or Right Exercise Price Of Warrants Or Rights1 ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1	6.00
CY2015	us-gaap	Stock Issued During Period Value New Issues StockIssuedDuringPeriodValueNewIssues	2916065	USD
CY2015	cyrx	Stockissued During Period Value New Issues1 StockissuedDuringPeriodValueNewIssues1	1691506	USD
CY2014	us-gaap	Stock Issued During Period Value Conversion Of Convertible Securities StockIssuedDuringPeriodValueConversionOfConvertibleSecurities	4127201	USD
CY2015	us-gaap	Stock Issued During Period Value Conversion Of Convertible Securities StockIssuedDuringPeriodValueConversionOfConvertibleSecurities	1766997	USD
CY2015	cyrx	Adjustments To Additional Paid In Capital Fair Value Of Convertible Debt And Warrants With Conversion Feature AdjustmentsToAdditionalPaidInCapitalFairValueOfConvertibleDebtAndWarrantsWithConversionFeature	0	USD
CY2015	us-gaap	Adjustments To Additional Paid In Capital Convertible Debt With Conversion Feature AdjustmentsToAdditionalPaidInCapitalConvertibleDebtWithConversionFeature	826919	USD
CY2015	us-gaap	Stock Issued During Period Value Restricted Stock Award Gross StockIssuedDuringPeriodValueRestrictedStockAwardGross	17400	USD
CY2015	cyrx	Adjustments To Additional Paid In Capital Warrant Issued Related Party Notes Payable AdjustmentsToAdditionalPaidInCapitalWarrantIssuedRelatedPartyNotesPayable	280370	USD
CY2015	us-gaap	Adjustments To Additional Paid In Capital Warrant Issued AdjustmentsToAdditionalPaidInCapitalWarrantIssued	458937	USD
CY2014	cyrx	Debt Conversion Converted Instrument Related Party Amount Warrant Issued DebtConversionConvertedInstrumentRelatedPartyAmountWarrantIssued	0	USD
CY2014	us-gaap	Adjustments To Additional Paid In Capital Warrant Issued AdjustmentsToAdditionalPaidInCapitalWarrantIssued	478229	USD
CY2015	cyrx	Discount Price Per Share Percentage DiscountPricePerSharePercentage	0.2	pure
CY2015	cyrx	Percentage Of Assets Acquisition PercentageOfAssetsAcquisition	0.81	pure
CY2015Q2	us-gaap	Stockholders Equity Reverse Stock Split StockholdersEquityReverseStockSplit	1-for-12
CY2015	cyrx	Estimated Base Rent Under Lease EstimatedBaseRentUnderLease	9500	USD
CY2015Q1	us-gaap	Operating Leases Future Minimum Payments Due In Three Years OperatingLeasesFutureMinimumPaymentsDueInThreeYears	5500	USD
CY2014Q3	dei	Entity Public Float EntityPublicFloat	25056500	USD
CY2015	cyrx	Minimum Gross Proceeds From Beneficial Conversion Feature MinimumGrossProceedsFromBeneficialConversionFeature	5000000	USD
CY2015	us-gaap	Debt Instrument Convertible Beneficial Conversion Feature DebtInstrumentConvertibleBeneficialConversionFeature	521000	USD
CY2014Q1	us-gaap	Cash Cash	159000	USD
CY2015Q1	us-gaap	Cash Cash	1300000	USD

Files In Submission

Name	View Source	Status
0001144204-15-032332-index-headers.html	Edgar Link	pending
0001144204-15-032332-index.html	Edgar Link	pending
0001144204-15-032332.txt	Edgar Link	pending
0001144204-15-032332-xbrl.zip	Edgar Link	pending
cyrx-20150331.xml	Edgar Link	completed
cyrx-20150331.xsd	Edgar Link	pending
cyrx-20150331_cal.xml	Edgar Link	unprocessable
cyrx-20150331_def.xml	Edgar Link	unprocessable
cyrx-20150331_lab.xml	Edgar Link	unprocessable
cyrx-20150331_pre.xml	Edgar Link	unprocessable
FilingSummary.xml	Edgar Link	unprocessable
Financial_Report.xls	Edgar Link	pending
Financial_Report.xlsx	Edgar Link	pending
R1.htm	Edgar Link	pending
R10.htm	Edgar Link	pending
R11.htm	Edgar Link	pending
R12.htm	Edgar Link	pending
R13.htm	Edgar Link	pending
R14.htm	Edgar Link	pending
R15.htm	Edgar Link	pending
R16.htm	Edgar Link	pending
R17.htm	Edgar Link	pending
R18.htm	Edgar Link	pending
R19.htm	Edgar Link	pending
R2.htm	Edgar Link	pending
R20.htm	Edgar Link	pending
R21.htm	Edgar Link	pending
R22.htm	Edgar Link	pending
R23.htm	Edgar Link	pending
R24.htm	Edgar Link	pending
R25.htm	Edgar Link	pending
R26.htm	Edgar Link	pending
R27.htm	Edgar Link	pending
R28.htm	Edgar Link	pending
R29.htm	Edgar Link	pending
R3.htm	Edgar Link	pending
R30.htm	Edgar Link	pending
R31.htm	Edgar Link	pending
R32.htm	Edgar Link	pending
R33.htm	Edgar Link	pending
R34.htm	Edgar Link	pending
R35.htm	Edgar Link	pending
R36.htm	Edgar Link	pending
R37.htm	Edgar Link	pending
R38.htm	Edgar Link	pending
R39.htm	Edgar Link	pending
R4.htm	Edgar Link	pending
R40.htm	Edgar Link	pending
R41.htm	Edgar Link	pending
R42.htm	Edgar Link	pending
R43.htm	Edgar Link	pending
R44.htm	Edgar Link	pending
R45.htm	Edgar Link	pending
R46.htm	Edgar Link	pending
R47.htm	Edgar Link	pending
R48.htm	Edgar Link	pending
R49.htm	Edgar Link	pending
R5.htm	Edgar Link	pending
R50.htm	Edgar Link	pending
R51.htm	Edgar Link	pending
R52.htm	Edgar Link	pending
R53.htm	Edgar Link	pending
R54.htm	Edgar Link	pending
R55.htm	Edgar Link	pending
R56.htm	Edgar Link	pending
R57.htm	Edgar Link	pending
R58.htm	Edgar Link	pending
R59.htm	Edgar Link	pending
R6.htm	Edgar Link	pending
R60.htm	Edgar Link	pending
R61.htm	Edgar Link	pending
R62.htm	Edgar Link	pending
R63.htm	Edgar Link	pending
R7.htm	Edgar Link	pending
R8.htm	Edgar Link	pending
R9.htm	Edgar Link	pending
report.css	Edgar Link	pending
Show.js	Edgar Link	pending
tlogo.jpg	Edgar Link	pending
v410289_10k.htm	Edgar Link	pending
v410289_ex10-42.htm	Edgar Link	pending
v410289_ex21.htm	Edgar Link	pending
v410289_ex23-1.htm	Edgar Link	pending
v410289_ex3-7.htm	Edgar Link	pending
v410289_ex3-7a.jpg	Edgar Link	pending
v410289_ex3-7b.jpg	Edgar Link	pending
v410289_ex31-1.htm	Edgar Link	pending
v410289_ex31-2.htm	Edgar Link	pending
v410289_ex32-1.htm	Edgar Link	pending
v410289_ex32-2.htm	Edgar Link	pending

Create your account

Find Stocks Worth Researching

Deeply Understand Businesses

Value Businesses Intelligently

$CYRX
Cryoport, Inc. Stock $cyrx

2015 Q2 Form 10-K Financial Statement

#000114420415032332 Filed on May 19, 2015

Income Statement

Balance Sheet

Cashflow Statement

Facts In Submission

Files In Submission

$CYRX Cryoport, Inc. Stock $cyrx

2015 Q2 Form 10-K Financial Statement

#000114420415032332 Filed on May 19, 2015

Income Statement

Balance Sheet

Cashflow Statement

Facts In Submission

Files In Submission

$CYRX
Cryoport, Inc. Stock $cyrx